Loading stock data…
XERS
$6.28+0.15 (+2.53%)
Market ClosedLast close May 1
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xeris Biopharma Holdings, Inc. in the Healthcare sector is trading at $6.28. The stock is currently 38% below its 52-week high of $10.08, remaining 11.0% below its 200-day moving average. Technical signals show neutral RSI of 59 and bullish MACD crossover, explaining why XERS maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.28
Potential Downside
100%
Whystock Fair Value$0.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.03B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.05%
Volume
Today's trading volume
1.38M
Recent News
Does Record Q4 Results, Robust 2026 Guidance and Recorlev Patent Suit Change The Bull Case For Xeris (XERS)?
Earlier in 2026, Xeris Biopharma reported a record quarter of revenue growth and profitability for Q4 2025 and issued 2026 guidance targeting over 30% adjusted EBITDA growth and US$375 million to US$390 million in total revenue. At the same time, Xeris filed a patent infringement lawsuit to block generic versions of Recorlev until its patent expiry in 2040, underscoring management’s focus on protecting a key revenue source. Now we’ll examine how this combination of record profitability and...
Xeris Biopharma Balances New Profitability With Recorlev Patent Battles
Xeris Biopharma Holdings (NasdaqGS:XERS) has reported financial self-sustainability and its first full year of net income. Recent results are supported by strong revenue contribution from its core product portfolio. The company is pursuing multiple patent infringement lawsuits to protect Recorlev from generic challengers. At a share price of $6.02, Xeris Biopharma sits after a 63.1% return over the past year and a 3-year gain of 315.2%. The stock has seen a 7-day return of an 8.5% decline,...
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
Xeris Biopharma Holdings Inc (XERS) reports robust financial performance with significant revenue growth and strategic plans for 2026, despite ongoing legal challenges.
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary
Moby summary of Xeris Biopharma Holdings, Inc.'s Q4 2025 earnings call
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
Now as we enter 2026, we do so with clear momentum positioned to drive rapid revenue growth, execute on our advanced pipeline and thoughtfully prepare for even greater opportunities ahead. The performance you delivered in 2025 and the strength of our outlook for 2026 is a direct result of your extraordinary commitment, focus and disciplined execution across every part of our enterprise. Fourth quarter total revenue grew 43% year-over-year to nearly $86 million.